arrow
H

Helmut Butzkueven

monash university
H指数:73
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Patient-reported symptom burden after chimeric antigen receptor T-cell therapy

患者报告的症状负担在嵌合抗原受体T细胞疗法后的情况

2026-09-160
PRE
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study

在记录有化疗暴露的人群中,癌症诊断后的多发性硬化结局:一项真实世界MSBase研究

2026-08-020
PRE
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy

在嵌合抗原受体T细胞疗法后6个月内,免疫效应细胞相关神经毒性综合征后的认知恢复

2026-07-011
PRE
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion

多发性硬化疾病修正疗法对慢性病灶组织扩张的影响

2026-07-010
PRE
Cross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis

横断面脑容积测量与复发-缓解型多发性硬化中的残疾结局

2026-04-010
OAAI
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

抗CD20疗法与S1P受体调节剂在迟发性多发性硬化中的比较疗效:来自MSBase注册研究的真实世界证据

2026-03-260
PRE
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

多发性硬化疾病 modifying therapies 之间水平切换的实效性:MSBase 注册数据库的回顾性分析

2025-12-230
PRE
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary utility for subacute cognitive monitoring after immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy

重复性神经心理状态评估量表(RBANS):在嵌合抗原受体T细胞疗法后,针对免疫效应细胞相关神经毒性综合征亚急性认知监测的初步应用价值

2025-11-260
PRE
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI